Clinically Tested CIG-NO

The following is a summary of the results of the Clinical Trial "An Open Evaluation of the Tobacco Aversion Caused by Plantago Major Tincture in Heavy Smokers," which was conducted for the purpose of demonstrating that Plantago Major, the active ingredient in CIG-NO causes an aversion to tobacco.

The test was conducted by a certified clinical laboratory on heavy smokers who did not wish to stop smoking. The results concluded that 83% of the subjects felt an aversion to tobacco for an extended period of time.

This highly positive correlation confirming the aversion to tobacco caused by Plantago Major suggests that CIG-NO can be used to help a person to stop smoking or to reduce the regular use of cigarettes or other tobacco products.

• Four out of five (83%) of test subjects "recorded some aversion to smoking..."
• All subjects were heavy smokers (at least a pack a day) with a history of smoking (at least 5 years)
• The aversion created was reported as "a decrease in pleasure of smoking..."

Certified Clinical Testing Facility:
Essex Testing, Inc., Verona, NJ
Technical Director: C.J. DiFiglia, M.D.

For complete Clinical Testing results, please call 1-800-431-2582.

Ten Years in the Making

Ten years ago a patient asked Dr. Mary Cody, originator of CIG-NO, to "find something for my smoking habit." Those few words launched the CIG-NO revolution. Dr. Cody soon began to experiment with Plantago Major, the active ingredient in CIG-NO. After careful testing, Dr. Cody hit upon just the right formulation that has led to CIG-NO Smoking Deterrent Spray, Caps and Drops. Today's CIG-NO is a potent health tool: a cessation remedy for smokers who want to quit... an everyday management tool for the smokers who want to control their smoking.

.

.